
LT002 The Therapeutically Inflamed Tumor Microenvironment Drives Melanoma Progression. Andrew Bradshaw. University of Pittsburgh, Pittsburgh, PA, United States.

LT003 Endothelin-1 drives invadopodia and cross-talk with submesothelial matrix invasion cell through ILK. Laura Rosanò. Institute of Molecular Biology and Pathology, CNR, Rome, Italy.

LT004 Immune suppression established by postpartum liver involution promotes liver metastasis. Alexandra Quackenbush. Oregon Health & Science University, Portland, OR, United States.

LT005 Tumor-intrinsic gain of function p53 R172H mutation drives accumulation of neutrophils in the pancreatic tumor microenvironment that promotes resistance to immunotherapy. Despina Siolas. NYU Langone Health, NY, United States.

LT006 NK cells from prostate cancer patients acquire a pro-angiogenic phenotype and polarize macrophages towards a M2-like/TAM subset. Adriana Albini. IRCCS MultiMedica, Sesto San Giovanni, MI, Italy.

LT008 Mapping the evolution of T cell states during response and resistance to adoptive cellular therapy. Pavan Bachireddy. Dana-Farber Cancer Institute, Boston, MA, United States.


LT010 Pleiotrophin drives pro-metastatic immune niche within breast tumor microenvironment. Debolina Ganguly. UT Southwestern Medical Center, Dallas, TX, United States.

LT011 Pharmacological blockade of platelet-CysLT1 receptor counteracts platelet protumoral action and prevents breast cancer cell metastasis to bone and lungs. Lou Saier. Université Claude Bernard Lyon 1, Lyon, France.

LT012 The prolyl isomerase PIN1 plays a critical role in fibroblast plasticity to impact pancreatic cancer. Ellen Langer. Oregon Health & Science University, Portland, OR, United States.

LT013 Endocrine-exocrine signaling is a driver of obesity-associated pancreatic ductal adenocarcinoma. Mandar Muzumdar. Yale University School of Medicine, New Haven, CT, United States.

LT014 Extracellular matrix stiffness regulates cellular response to anticancer drugs in breast and lung cancer cells. Atul Bharde. Savitribai Phule Pune University, Pune, India.

LT016 Mechanosurveillance eliminates disseminated cancer cells by sensing their mechanical compliance. Ekrem Emrah Er. The University of Illinois at Chicago, Chicago, IL, United States.

LT017 ECM mechanical and metabolic architecture during early ductal invasions: integrating in silico modeling, histology-based machine learning and mechanobiology. Katarzyna Rejniak. Moffitt Cancer Center, TAMPA, FL, United States.

LT018 The perivascular niche protects ALK+ lymphoma cells from ALK inhibition through the CCL19/21-CCR7 axis. Claudia Voena. University of Torino, Torino, Italy.

LT019 The synaptic protein netrin G1 ligand (NGL-1) modulates the immunosuppressive environment in pancreatic cancer. Debora Vendramini-Costa. Fox Chase Cancer Center, Philadelphia, PA, United States.

LT020 Cancer associated fibroblasts in the tumor microenvironment maintain ovarian cancer stem cells through non-canonical Wnt5a signaling. Yiming Fang. Indiana University School of Medicine-Bloomington, Bloomington, IN, United States.

LT021 Targeting AXL favors an Anti-Tumorigenic Tumor Microenvironment that enhances Immunotherapy Responses by decreasing HIF-1a levels in cancer cells. Marie-Anne Goyette. Montreal Clinical Research Institute, Montréal, QC, Canada.

LT022 The AML microenvironment catalyzes a step-wise evolution to gilteritinib resistance. Sunil Joshi. Oregon Health & Science University, Portland, OR, United States.